Incidences of Deep Molecular Responses and Treatment-Free Remission in de Novo CP-CML Patients

SIMPLE SUMMARY: Tyrosine kinase inhibitors (TKI) can be safely discontinued in chronic myeloid leukemia patients. Achieving a sustained deep molecular response (DMR) before stop is recommended. Currently, the proportion of patients who achieve a sustained DMR remains to be determined. Based on the f...

Descripción completa

Detalles Bibliográficos
Autores principales: Etienne, Gabriel, Dulucq, Stéphanie, Bauduer, Fréderic, Adiko, Didier, Lifermann, François, Dagada, Corinne, Lenoir, Caroline, Schmitt, Anna, Klein, Emilie, Madene, Samia, Fort, Marie-Pierre, Bijou, Fontanet, Moldovan, Marius, Turcq, Beatrice, Robbesyn, Fanny, Durrieu, Françoise, Versmée, Laura, Katsahian, Sandrine, Faberes, Carole, Lascaux, Axelle, Mahon, François-Xavier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565328/
https://www.ncbi.nlm.nih.gov/pubmed/32899879
http://dx.doi.org/10.3390/cancers12092521

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565328/
https://www.ncbi.nlm.nih.gov/pubmed/32899879
http://dx.doi.org/10.3390/cancers12092521

Ejemplares similares